OncoMed Pharmaceuticals, Inc (OMED) Covered Calls

OncoMed Pharmaceuticals, Inc covered calls OncoMed Pharmaceuticals Inc is a clinical development-stage biotechnology company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells.

There are no covered calls available for OncoMed Pharmaceuticals, Inc.

Born To Sell's covered call screener gives you full search capabilities so you can find stocks and ETFs that make good covered call candidates.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

OncoMed Pharmaceuticals, Inc. is a clinical development-stage biotechnology company that discovers and develops first-in-class protein therapeutics targeting cancer stem cells. The company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. It has six anti-cancer stem cell product candidates in clinical trials: Demcizumab (OMP-21M18), Anti-DLL4/VEGF Bispecific (OMP-305B8), Tarextumab (Anti-Notch2/3, OMP-59R5), Brontictuzumab (Anti-Notch1, OMP-52M5), Vantictumab (Anti-Fzd7, OMP-18R5), RSPO-LGR. Its pipeline also includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways, including the RSPO-LGR pathway, Wnt 3rd Biologic and Wnt Small Molecules. The company was founded by Drs. Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA.